Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Financial performance shows improvement in net loss and operating expenses, yet cash reserves declined. The Q&A indicates confidence in future growth and sales strategies, but management's vague responses on certain metrics raise concerns. The guidance suggests positive future growth, but current financial metrics and lack of clear guidance on some fronts balance out the optimism, leading to a neutral sentiment.
Key Financial Performance
Total worldwide revenue $20.6 million in Q1 2026, a 9% decrease from $22.5 million in Q1 2025. The decline was attributed to operational challenges and the absence of sales to the distributor in China.
U.S. revenue $13.3 million in Q1 2026, a 7% decrease from $14.2 million in Q1 2025. The decline was due to internal operational challenges.
International revenue $7.3 million in Q1 2026, a 12% decrease from $8.3 million in Q1 2025 and a 21% decrease on a constant currency basis. The decline was fully attributable to the absence of sales to the distributor in China. Excluding China, international markets grew 22% year-over-year and 9% on a constant currency basis.
Gross margin 78% in Q1 2026, compared to 73% in Q1 2025. The increase was driven by a lower mix of distributor sales in international markets.
Total operating expenses $29 million in Q1 2026, a 6% decrease from Q1 2025. Excluding stock-based compensation and restructuring costs, operating expenses decreased 8% year-over-year due to cost alignment efforts.
R&D expenses $4.9 million in Q1 2026, compared to $4.8 million in Q1 2025. The slight increase reflects ongoing investments in growth initiatives.
Sales, general and administrative expenses $24.1 million in Q1 2026, compared to $26.1 million in Q1 2025. The decrease was due to cost reduction initiatives.
Net loss $13.7 million in Q1 2026, compared to $14.4 million in Q1 2025. The improvement was driven by cost reduction efforts.
Adjusted EBITDA loss $8.5 million in Q1 2026, consistent with Q1 2025. Excluding one-time restructuring charges, adjusted EBITDA loss was $7 million, an 18% improvement year-over-year.
Cash, cash equivalents, and marketable securities $61.6 million as of March 31, 2026, a decrease of $8.2 million from December 31, 2025. The decrease was due to cash burn, which was reduced through cost restructuring and a new credit facility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AeriSeal program: The CONVERT II pivotal trial is progressing well, with enrollment expected to complete in 2027. This program aims to expand the total addressable market by approximately 20% globally, serving as both a revenue driver and market expander for Zephyr Valves.
U.S. market: Efforts to reaccelerate U.S. sales growth include filling sales leadership and field sales roles, stabilizing sales turnover, and focusing on high-impact activities such as setting up valve programs and engaging with COPD-oriented clinicians.
International market: International revenue decreased by 12% due to the absence of sales to the distributor in China. Excluding China, other international markets grew 22% year-over-year. Sales to China are expected to resume in the second half of 2026.
Cost restructuring: A cost restructuring initiative reduced ongoing operating expenses by over 10%, aligning spending with strategic priorities and improving expense trajectory.
Cash management: Secured a $60 million credit facility with a 5-year interest-only structure, extending debt maturity to 2031 and providing access to an additional $20 million. Cash burn for 2026 is expected to decrease to $23 million from $32 million in 2025.
Sales strategy: Refocused commercial strategy in the U.S. includes leadership transparency, streamlined selling priorities, and direct-to-patient efforts in established treating centers.
Market expansion strategy: The AeriSeal program is a strategic initiative to expand the market for Zephyr Valves, with significant potential for medium to long-term growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Operational and Executional Challenges: The company is addressing internal operational and executional challenges that have led to recent underperformance. Efforts are being made to reaccelerate U.S. sales growth, advance clinical initiatives, and align cost structures to drive profitability.
Sales Turnover: Sales turnover has been a significant issue, though it has stabilized over the last six months. High turnover previously impacted sales performance and team productivity.
Revenue Decline: Total worldwide revenue decreased by 9% year-over-year, with U.S. revenue down 7% and international revenue down 12%. The decline in international revenue is attributed to the absence of sales to the distributor in China due to pending renewal of the Chinese registration certificate.
China Market Access: The company is awaiting the renewal of its Chinese registration certificate, which has halted sales to its distributor in China. This has negatively impacted international revenue and is expected to continue until the second half of 2026.
Cost Structure and Cash Burn: The company executed a cost restructuring initiative to reduce operating expenses by over 10%. Despite these efforts, the company still expects to burn $23 million in cash for the full year 2026, though this is an improvement from 2025.
Clinical Trial Progress: The CONVERT II pivotal trial for the AeriSeal program is progressing, but enrollment completion is not expected until 2027. Delays in clinical trials could impact the timeline for market expansion and revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2026 Revenue Guidance: Pulmonx expects to achieve revenue guidance of $90 million to $92 million for the full year 2026, with a return to global growth in the back half of the year.
U.S. Sales Growth: The company anticipates reaccelerating U.S. sales growth in the latter half of 2026, driven by a stabilized sales team and a refocused commercial strategy.
AeriSeal Program and Market Expansion: Pulmonx aims to complete enrollment for the CONVERT II pivotal trial in 2027, potentially expanding the total addressable market by approximately 20% globally. AeriSeal is expected to serve as both a revenue driver and a market expander for Zephyr Valves over the medium to long term.
Gross Margin Outlook: Gross margin for the full year 2026 is expected to be approximately 75%, with higher margins in the first half of the year and lower margins in the second half due to the mix of distributor sales.
Operating Expenses: Full year 2026 operating expenses are projected to fall between $113 million and $115 million, inclusive of approximately $19 million of noncash stock-based compensation expense.
Cash Burn Reduction: Pulmonx expects to burn approximately $23 million of cash for the full year 2026, a significant reduction from the $32 million burned in 2025.
International Revenue Growth: International revenue growth is expected to resume in the second half of 2026, contingent on the renewal of the Chinese registration certificate and continued strength in other international markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details about the strategies being used to accelerate sales growth and the productivity expectations for the new sales team?
A:The company has narrowed the focus of its U.S. sales force to improve efficiency, emphasizing high-quality and efficient valve programs. They are engaging COPD physicians to drive patients into centers and gaining administrative support for resource execution. The sales team is being trained and brought up to speed quickly, with positive early results. The company is on track with its expectations for the sales force's progress.
Q:What is the growth cadence for 2026, and how confident are you in achieving the guidance laid out?
A:The company expects sequential quarterly year-over-year growth improvement throughout the year, flipping to positive growth in the back half and exiting with double-digit growth in both U.S. and international markets. Confidence stems from the new sales hires reaching productivity within 6-9 months and focused strategies taking hold. International growth is expected to improve due to timing of sales into China and strong underlying business performance.
Q:What is driving the strong U.S. account additions in Q1, and what metrics are being used to monitor the revamped sales force's success?
A:The addition of 15 U.S. accounts in Q1 is attributed to the refocused sales team ramping up quickly. The company maintains a target of 10 new accounts per quarter. Metrics for success include bringing sales reps up to speed, leveraging best practices, and monitoring leading indicators like StratX performance.
Q:What are the long-term growth aspirations for the company, and do you expect to achieve double-digit growth?
A:The company expects to achieve double-digit growth, particularly as it addresses past challenges like losing sales reps and doing too many things simultaneously. International markets have shown consistent double-digit growth, and the U.S. market is expected to follow suit. The company is also working on TAM expanders like AeriSeal to support growth.
Q:What is the status of the Chinese registration renewal, and how does it impact international growth expectations?
A:The renewal of the Chinese registration certificate is expected in the back half of the year and is considered an administrative process. The resumption of sales in China will be gradual, and the current guidance does not rely heavily on China for the second half. Tough comps from China sales in the first half of 2025 will be anniversaryed, and international growth will reflect the strong underlying business performance.
Q:How does the company prioritize and quantify same-store productivity across different account quartiles?
A:The company focuses on the top quartile of accounts to leverage best practices and momentum. New accounts are also prioritized, with higher standards for onboarding and immediate procedural activity. The bottom quartiles are less of a focus compared to supporting strong-performing accounts and new accounts.
Q:What is the current approach to LungTraX, and what factors influence its expansion?
A:The company has shifted to a more focused approach for LungTraX, targeting accounts where it can deliver significant ROI. While it is not deemphasized, the company has learned that the technology works best in specific account types. The setup process takes time, but once operational, it contributes effectively to account performance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific percentages of accounts using LungTraX and did not quantify same-store productivity across quartiles. Additionally, they did not provide detailed metrics for monitoring the revamped sales force's success or elaborate on the exact ROI thresholds for expanding LungTraX.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AeriSeal driver
Chief Officer
Officer Chief
Pulmonx update
Relations statement
Sung Chief
Today ability
Valves champion
Valves medium
ability enrollment
ability return
ability review
action expense
activity priority
administrator resourcing
affair Today
afternoon Sung
approach focus
approach quality
burn investment
challenge underperformance
champion service
clinician hospital
closing conviction
conference Investor
conference pleasure
conviction market
cost reduction
course reacceleration
culture place
culture sale
development afternoon
driver closing
driver market
effort challenge
effort transparency
element people
field
improvement
today Pulmonx
LUNG Transcript
Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral5-12
Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call presents a mixed outlook. Financial performance shows improvement in net loss and operating expenses, yet cash reserves declined. The Q&A indicates confidence in future growth and sales strategies, but management's vague responses on certain metrics raise concerns. The guidance suggests positive future growth, but current financial metrics and lack of clear guidance on some fronts balance out the optimism, leading to a neutral sentiment.
Pulmonx Corporation (LUNG) Q4 2025 Earnings Call Transcript
Unknown3-4
The earnings call presents mixed signals. Financial performance shows improvements in net loss and EBITDA, but cash reserves are declining. The sales force restructuring is positive, yet growth is not expected until late 2026. Cost management is effective, but management's lack of clarity on key metrics raises concerns. Market conditions are favorable, but significant growth drivers like Japan and China are limited. Overall, the outlook is balanced, resulting in a neutral sentiment.
Pulmonx Corporation (LUNG) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reveals mixed financial results with modest revenue growth and increased expenses, particularly in R&D. The guidance revision downward and management's inability to provide clear answers during the Q&A suggest challenges in execution and strategic direction. While international growth and gross margin improvements are positives, the lack of clarity on U.S. growth and strategic pathways, along with cash burn, contribute to a negative sentiment. The market is likely to react negatively to these uncertainties, resulting in a potential stock price decline of -2% to -8%.
LUNG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
